Demographic, anthropometric, clinical, and biochemical characteristics of study patients
| . | Total . |
|---|---|
| . | n = 33 . |
| Demographic information | |
| Age, years | 67.2 ± 10.5 |
| Sex, n (%) | |
| Male | 30 (90.9) |
| Female | 3 (9.1) |
| Smoking (n, %) | |
| Current smoker | 15 (45.5) |
| Former or non-smoker | 18 (54.5) |
| Anthropometric measures | |
| BMI, kg/m2 | 26.8 ± 4.6 |
| Waist circumference, cm | 102.6 ± 15.4 |
| WHtR, cm/cm | 0.60 ± 0.08 |
| WHR, cm/cm | 0.98 ± 0.12 |
| EAT thickness (mm) | 6.2 ± 2.5 |
| Biochemistry | |
| Fasting glucose, mg/dL | 95.6 ± 29.1 |
| Fasting insulin, μU/mL | 9.2 ± 8.5 |
| HbA1c, % | 4.7 ± 1.2 |
| HOMA index | 2.1 ± 2.0 |
| Total cholesterol, mg/dL | 158.1 ± 35.1 |
| HDL cholesterol, mg/dL | 42.9 ± 11.7 |
| Triglycerides, mg/dL | 122.6 ± 49.6 |
| C-reactive protein, mg/dL | 0.95 ± 1.8 |
| ALT/GPT, u/L | 35.9 ± 33.9 |
| AST/GOT, u/L | 38.7 ± 48.5 |
| Comorbidities, n (%) | |
| Hypertension | 26 (78.8) |
| Dyslipidaemia | 21 (63.6) |
| Type 2 diabetes mellitus | 10 (30.3) |
| General obesity | 3 (9.1) |
| Abdominal obesity | 19 (57.6) |
| Medications, n (%) | |
| Aspirin | 21 (63.6) |
| ACEi/ARB | 25 (75.8) |
| Anti-diabetic agents (metformin) | 8 (24.2) |
| β-Blockers | 17 (51.5) |
| Calcium channel blockers | 6 (18.1) |
| Statins | 23 (69.7) |
| . | Total . |
|---|---|
| . | n = 33 . |
| Demographic information | |
| Age, years | 67.2 ± 10.5 |
| Sex, n (%) | |
| Male | 30 (90.9) |
| Female | 3 (9.1) |
| Smoking (n, %) | |
| Current smoker | 15 (45.5) |
| Former or non-smoker | 18 (54.5) |
| Anthropometric measures | |
| BMI, kg/m2 | 26.8 ± 4.6 |
| Waist circumference, cm | 102.6 ± 15.4 |
| WHtR, cm/cm | 0.60 ± 0.08 |
| WHR, cm/cm | 0.98 ± 0.12 |
| EAT thickness (mm) | 6.2 ± 2.5 |
| Biochemistry | |
| Fasting glucose, mg/dL | 95.6 ± 29.1 |
| Fasting insulin, μU/mL | 9.2 ± 8.5 |
| HbA1c, % | 4.7 ± 1.2 |
| HOMA index | 2.1 ± 2.0 |
| Total cholesterol, mg/dL | 158.1 ± 35.1 |
| HDL cholesterol, mg/dL | 42.9 ± 11.7 |
| Triglycerides, mg/dL | 122.6 ± 49.6 |
| C-reactive protein, mg/dL | 0.95 ± 1.8 |
| ALT/GPT, u/L | 35.9 ± 33.9 |
| AST/GOT, u/L | 38.7 ± 48.5 |
| Comorbidities, n (%) | |
| Hypertension | 26 (78.8) |
| Dyslipidaemia | 21 (63.6) |
| Type 2 diabetes mellitus | 10 (30.3) |
| General obesity | 3 (9.1) |
| Abdominal obesity | 19 (57.6) |
| Medications, n (%) | |
| Aspirin | 21 (63.6) |
| ACEi/ARB | 25 (75.8) |
| Anti-diabetic agents (metformin) | 8 (24.2) |
| β-Blockers | 17 (51.5) |
| Calcium channel blockers | 6 (18.1) |
| Statins | 23 (69.7) |
Data are expressed as n (%) or mean (± standard deviation). Abdominal obesity (waist circumference ≥102 cm for males, ≥ 88 cm for females); general obesity (BMI ≥ 30 kg/m2)
BMI, body mass index; WHtR, waist-to-height ratio; WHR, waist-to-hip ratio; EAT, epicardial adipose tissue; HbA1c, haemoglobin A1c; HOMA, homoeostasis model assessment of insulin resistance; ALT/GPT, alanine aminotransferase/glutamat-pyruvat-transaminase; AST/GOT, aspartate aminotransferase/glutamic-oxaloacetic transaminase; ACEi, angiotensinogen-converting enzyme inhibitor; ARB, angiotensin receptor blockade.
Demographic, anthropometric, clinical, and biochemical characteristics of study patients
| . | Total . |
|---|---|
| . | n = 33 . |
| Demographic information | |
| Age, years | 67.2 ± 10.5 |
| Sex, n (%) | |
| Male | 30 (90.9) |
| Female | 3 (9.1) |
| Smoking (n, %) | |
| Current smoker | 15 (45.5) |
| Former or non-smoker | 18 (54.5) |
| Anthropometric measures | |
| BMI, kg/m2 | 26.8 ± 4.6 |
| Waist circumference, cm | 102.6 ± 15.4 |
| WHtR, cm/cm | 0.60 ± 0.08 |
| WHR, cm/cm | 0.98 ± 0.12 |
| EAT thickness (mm) | 6.2 ± 2.5 |
| Biochemistry | |
| Fasting glucose, mg/dL | 95.6 ± 29.1 |
| Fasting insulin, μU/mL | 9.2 ± 8.5 |
| HbA1c, % | 4.7 ± 1.2 |
| HOMA index | 2.1 ± 2.0 |
| Total cholesterol, mg/dL | 158.1 ± 35.1 |
| HDL cholesterol, mg/dL | 42.9 ± 11.7 |
| Triglycerides, mg/dL | 122.6 ± 49.6 |
| C-reactive protein, mg/dL | 0.95 ± 1.8 |
| ALT/GPT, u/L | 35.9 ± 33.9 |
| AST/GOT, u/L | 38.7 ± 48.5 |
| Comorbidities, n (%) | |
| Hypertension | 26 (78.8) |
| Dyslipidaemia | 21 (63.6) |
| Type 2 diabetes mellitus | 10 (30.3) |
| General obesity | 3 (9.1) |
| Abdominal obesity | 19 (57.6) |
| Medications, n (%) | |
| Aspirin | 21 (63.6) |
| ACEi/ARB | 25 (75.8) |
| Anti-diabetic agents (metformin) | 8 (24.2) |
| β-Blockers | 17 (51.5) |
| Calcium channel blockers | 6 (18.1) |
| Statins | 23 (69.7) |
| . | Total . |
|---|---|
| . | n = 33 . |
| Demographic information | |
| Age, years | 67.2 ± 10.5 |
| Sex, n (%) | |
| Male | 30 (90.9) |
| Female | 3 (9.1) |
| Smoking (n, %) | |
| Current smoker | 15 (45.5) |
| Former or non-smoker | 18 (54.5) |
| Anthropometric measures | |
| BMI, kg/m2 | 26.8 ± 4.6 |
| Waist circumference, cm | 102.6 ± 15.4 |
| WHtR, cm/cm | 0.60 ± 0.08 |
| WHR, cm/cm | 0.98 ± 0.12 |
| EAT thickness (mm) | 6.2 ± 2.5 |
| Biochemistry | |
| Fasting glucose, mg/dL | 95.6 ± 29.1 |
| Fasting insulin, μU/mL | 9.2 ± 8.5 |
| HbA1c, % | 4.7 ± 1.2 |
| HOMA index | 2.1 ± 2.0 |
| Total cholesterol, mg/dL | 158.1 ± 35.1 |
| HDL cholesterol, mg/dL | 42.9 ± 11.7 |
| Triglycerides, mg/dL | 122.6 ± 49.6 |
| C-reactive protein, mg/dL | 0.95 ± 1.8 |
| ALT/GPT, u/L | 35.9 ± 33.9 |
| AST/GOT, u/L | 38.7 ± 48.5 |
| Comorbidities, n (%) | |
| Hypertension | 26 (78.8) |
| Dyslipidaemia | 21 (63.6) |
| Type 2 diabetes mellitus | 10 (30.3) |
| General obesity | 3 (9.1) |
| Abdominal obesity | 19 (57.6) |
| Medications, n (%) | |
| Aspirin | 21 (63.6) |
| ACEi/ARB | 25 (75.8) |
| Anti-diabetic agents (metformin) | 8 (24.2) |
| β-Blockers | 17 (51.5) |
| Calcium channel blockers | 6 (18.1) |
| Statins | 23 (69.7) |
Data are expressed as n (%) or mean (± standard deviation). Abdominal obesity (waist circumference ≥102 cm for males, ≥ 88 cm for females); general obesity (BMI ≥ 30 kg/m2)
BMI, body mass index; WHtR, waist-to-height ratio; WHR, waist-to-hip ratio; EAT, epicardial adipose tissue; HbA1c, haemoglobin A1c; HOMA, homoeostasis model assessment of insulin resistance; ALT/GPT, alanine aminotransferase/glutamat-pyruvat-transaminase; AST/GOT, aspartate aminotransferase/glutamic-oxaloacetic transaminase; ACEi, angiotensinogen-converting enzyme inhibitor; ARB, angiotensin receptor blockade.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
